Clinical Trials Browser

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT03734198 2025-11-26

IDA53

Phase 2 Active not recruiting

29 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02956382 2025-07-18

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Phase 1/2 Completed

24 enrolled 18 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Recurrence

NCT03734016 2025-03-30

ALPINE

Phase 3 Completed

652 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01833039 2025-02-03

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Approved for marketing

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT03679624 2023-10-23

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Phase 2 Terminated

1 enrolled 8 charts

Lymphoid

Hypergammaglobulinemia, Waldenstrom Macroglobulinemia, Recurrence

NCT02309580 2023-05-09

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Phase 1 Completed

14 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell

NCT03876028 2023-01-31

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1 Terminated

10 enrolled

Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02419560 2022-05-24

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

Phase 1 Completed

37 enrolled

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

58 enrolled

Lymphoid

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT03617484 2020-06-22

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Phase 2 Withdrawn

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT01611090 2020-03-03

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Completed

578 enrolled 21 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01614821 2020-01-21

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Phase 2 Completed

63 enrolled 12 charts

Lymphoid

Waldenstrom Macroglobulinemia, Recurrence

NCT01578707 2019-12-18

RESONATE™

Phase 3 Completed

391 enrolled 14 charts

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Phase 2 Unknown

72 enrolled

Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02269085 2019-02-28

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Phase 1 Terminated

8 enrolled

Lymphoid

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02437019 2017-03-20

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Approved for marketing

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02780830 2016-09-15

INHIBITOR

Phase 1 Withdrawn

Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse